Literature DB >> 9444685

Diagnosis and management of substance use disorders among inpatients with schizophrenia.

J E Kirchner1, R R Owen, C Nordquist, E P Fischer.   

Abstract

OBJECTIVE: The study examined the extent of clinical recognition of comorbid substance use disorders and the clinical management of these disorders among inpatients hospitalized for an acute exacerbation of schizophrenia.
METHODS: Medical records of 42 inpatients who met research diagnostic criteria for both schizophrenia and a current substance use disorder were reviewed for information about admission evaluation, inpatient management, discharge diagnosis, and disposition.
RESULTS: Alcohol use disorders were the most frequent co-occurring substance-related diagnoses, found for 86 percent of the dually diagnosed inpatients. Twenty-four patients (57 percent) did not receive a diagnosis of a substance-related disorder at admission, and 19 (45 percent) did not receive a substance-related diagnosis at discharge. Referral to inpatient or outpatient substance abuse treatment was documented for a minority of subjects.
CONCLUSION: The results suggest that improvements are needed in the process of clinical care for inpatients with schizophrenia who have co-occurring substance-related disorders. They highlight a need for education of health care providers and continuous quality improvement in this area.

Entities:  

Mesh:

Year:  1998        PMID: 9444685     DOI: 10.1176/ps.49.1.82

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  2 in total

1.  Schizophrenia, co-occurring substance use disorders and quality of care: the differential effect of a managed behavioral health care carve-out.

Authors:  Alisa B Busch; Richard G Frank; Anthony F Lehman; Shelly F Greenfield
Journal:  Adm Policy Ment Health       Date:  2006-05

2.  Substance use disorders in schizophrenia--clinical implications of comorbidity.

Authors:  Nora D Volkow
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.